Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey S Freeman

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cleveland Clinic Journal of Medicine|December 3, 2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitusJeffrey S Freeman
The Journal of the American Osteopathic Association|September 30, 2010
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugsJeffrey S Freeman
The Journal of the American Osteopathic Association|July 21, 2010
The increasing epidemiology of diabetes and review of current treatment algorithmsJeffrey S Freeman
The Journal of the American Osteopathic Association|June 28, 2008
Treating Hispanic patients for type 2 diabetes mellitus: special considerationsJeffrey S Freeman
Diabetes Forecast|September 29, 2005
Blood glucose in the hospital. Doctors are starting to see that tight glucose control saves livesJeffrey S Freeman
The Journal of the American Osteopathic Association|February 6, 2009
Insulin analog therapy: improving the match with physiologic insulin secretionJeffrey S Freeman
Current Diabetes Reports|April 29, 2010
Are analogue insulins superior to human insulin in clinical practice?Jeffrey S Freeman
The Journal of Family Practice|October 31, 2008
Why and when to implement incretin therapyJeffrey S Freeman, Jeff Unger
Expert Review of Clinical Pharmacology|December 7, 2011
Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology reviewJeffrey S Freeman, Benjamin Gross
American Journal of Therapeutics|November 17, 2012
What have we learned about the treatment of type 2 diabetes? The evolving paradigmsJeffrey S Freeman, Edward S Horton
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cleveland Clinic Journal of Medicine|December 3, 2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitusJeffrey S Freeman
The Journal of the American Osteopathic Association|September 30, 2010
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugsJeffrey S Freeman
The Journal of the American Osteopathic Association|July 21, 2010
The increasing epidemiology of diabetes and review of current treatment algorithmsJeffrey S Freeman
The Journal of the American Osteopathic Association|June 28, 2008
Treating Hispanic patients for type 2 diabetes mellitus: special considerationsJeffrey S Freeman
Diabetes Forecast|September 29, 2005
Blood glucose in the hospital. Doctors are starting to see that tight glucose control saves livesJeffrey S Freeman
The Journal of the American Osteopathic Association|February 6, 2009
Insulin analog therapy: improving the match with physiologic insulin secretionJeffrey S Freeman
Current Diabetes Reports|April 29, 2010
Are analogue insulins superior to human insulin in clinical practice?Jeffrey S Freeman
The Journal of Family Practice|October 31, 2008
Why and when to implement incretin therapyJeffrey S Freeman, Jeff Unger
Expert Review of Clinical Pharmacology|December 7, 2011
Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology reviewJeffrey S Freeman, Benjamin Gross
American Journal of Therapeutics|November 17, 2012
What have we learned about the treatment of type 2 diabetes? The evolving paradigmsJeffrey S Freeman, Edward S Horton
Pageof 3